oral glp 1 novo nordisk BREAKING: The FDA has approved the first GLP-1 pill for obesity, marking a major milestone in the weight-loss drug market and a potential inflection point for treatment access. The daily pill Eli Lilly Gets Speedy FDA

Burping smelled like eggs

Kem dng th Glutathione Niacinamide CHM l gii php chm sc da ton thn gip dng m su, h tr lm sng v u mu da hiu qu nh s kt hp gia Glutathione, Niacinamide, Tranexamic Acid v chit xut cc la m

E.KitteringhamN

Treating metabolic risk factors for developing MASLD, such as diabetes and obesity, can decrease the risk of developing MASLD

Bottom line: GLP-1 RAs can affect your electrolyte balance through multiple pathways both directly (by changing how your body processes sodium and insulin) and indirectly (by reducing your food and fluid intake or causing GI side effects)

Effectiveness Semaglutide patients typically see about 15% reduction in body weight, while Tirzepatide patients in clinical studies have lost closer to 20% or more